6-Phenyl-9-prop-2-enyl-3,4,9-triazatricyclo[11.3.1.02,7]heptadeca-1(16),2(7),3,5,13(17),14-hexaen-8-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-Phenyl-9-prop-2-enyl-3,4,9-triazatricyclo[11.3.1.02,7]heptadeca-1(16),2(7),3,5,13(17),14-hexaen-8-one
• 英文别名: 6-phenyl-9-prop-2-enyl-3,4,9-triazatricyclo[11.3.1.02,7]heptadeca-1(16),2(7),3,5,13(17),14-hexaen-8-one
• 化学式: C₂₃H₂₁N₃O
• 分子量: 355.4
• InChiKey: GBOFTKXUWIKTOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  46.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE
  申请人：AGENEBIO INC

  公开号：WO2014078377A1

  公开（公告）日：2014-05-22

  The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a α5 -containing GABAA receptor agonist and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some enbodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia.

  该发明涉及使用α5-含有的GABAA受体激动剂和抗精神病药物或它们的药用盐、水合物、溶剂合物、多形体的组合来治疗精神分裂症或双相情感障碍（特别是躁狂）。在某些实施方式中，这些方法和组合用于治疗与精神分裂症相关的一个或多个阳性和/或阴性症状，以及认知功能障碍。
• [EN] METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR AMÉLIORER LA FONCTION COGNITIVE
  申请人：GALLAGHER MICHELA

  公开号：WO2014153180A1

  公开（公告）日：2014-09-25

  This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a a5 -containing GABAA receptor agonist in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

  本发明涉及用于治疗与中枢神经系统（CNS）疾病相关的认知障碍的方法和组合物。具体而言，它涉及在需要或有风险的受试者中使用含有a5的GABAA受体激动剂与美拉替特或其衍生物或类似物结合，用于治疗与中枢神经系统（CNS）疾病相关的认知障碍，包括但不限于患有或有风险患上与年龄相关的认知障碍、轻度认知障碍（MCI）、遗忘性MCI（aMCI）、年龄相关记忆障碍（AAMI）、年龄相关认知衰退（ARCD）、痴呆症、阿尔茨海默病（AD）、前驱期AD、创伤后应激障碍（PTSD）、精神分裂症或躁郁症、肌萎缩侧索硬化、癌症治疗相关认知障碍、智力障碍、帕金森病（PD）、自闭症、强迫行为和物质成瘾。
• PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT
  申请人：Agenebio, Inc.

  公开号：EP2640391B1

  公开（公告）日：2015-11-11